Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T72245
|
||||
Former ID |
TTDR00277
|
||||
Target Name |
Alpha v beta 3 integrin receptor
|
||||
Gene Name |
ITGB3
|
||||
Synonyms |
Alpha v beta 3 integrin; Alpha(v)beta(3) Integrin; Alpha(v)beta(3) integrin receptor; Integrin alpha V beta 3; Integrin alpha-v beta-3; Integrin alphaVbeta3; Vitronectin Receptor; ITGB3
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Cancer [ICD9: 140-229; ICD10: C00-C96] | ||||
Peripheral vascular disease [ICD9: 443.9; ICD10: I73.9] | |||||
BioChemical Class |
Integrin
|
||||
UniProt ID | |||||
Sequence |
MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLG
SPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRP DDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFG AFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSR NRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCH VGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLS MDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDT VSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGT FECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFG KITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLL CSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRY CRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDIL VVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTF TNITYRGT |
||||
Structure |
1JV2; 1L5G; 1M1X; 1U8C; 3IJE; 4G1E; 4G1M; 4MMX; 4MMY; 4MMZ; 4O02; 4UM8; 4UM9
|
||||
Drugs and Mode of Action | |||||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
Reactome | Platelet degranulation | ||||
Cross-presentation of particulate exogenous antigens (phagosomes) | |||||
Elastic fibre formation | |||||
PECAM1 interactions | |||||
Molecules associated with elastic fibres | |||||
Integrin cell surface interactions | |||||
Laminin interactions | |||||
Syndecan interactions | |||||
ECM proteoglycans | |||||
Integrin alphaIIb beta3 signaling | |||||
SOS provides linkage to MAPK signaling for Integrins | |||||
p130Cas linkage to MAPK signaling for integrins | |||||
VEGFA-VEGFR2 Pathway | |||||
MAP2K and MAPK activation | |||||
WikiPathways | Osteoblast Signaling | ||||
Focal Adhesion | |||||
Class I MHC mediated antigen processing & | |||||
presentation | |||||
Syndecan interactions | |||||
Extracellular matrix organization | |||||
Elastic fibre formation | |||||
Primary Focal Segmental Glomerulosclerosis FSGS | |||||
Arrhythmogenic Right Ventricular Cardiomyopathy | |||||
Integrin-mediated Cell Adhesion | |||||
L1CAM interactions | |||||
Integrin cell surface interactions | |||||
Cell surface interactions at the vascular wall | |||||
Osteopontin Signaling | |||||
References | |||||
Ref 532373 | Synthesis of [18F]RGD-K5 by catalyzed [3 + 2] cycloaddition for imaging integrin alphavbeta3 expression in vivo. Nucl Med Biol. 2013 Jul;40(5):710-6. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.